SCHEMBL7880211

SCHEMBL7880211

Cc1cc(C)c(CO)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UHRF1 Q96T88 1/20 0.46
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 1/20 0.44
NOS3 P29474 1/20 0.41
NOS1 P29475 1/20 0.41
NOS2 P35228 1/20 0.41
LMNA P02545 2/20 0.40
PDXK O00764 3/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
AOX1 Q06278 1/20 0.39
TRIM24 O15164 1/20 0.38
TRIM33 Q9UPN9 1/20 0.38
SHBG P04278 1/20 0.36
SLC6A4 P31645 4/20 0.36
SLC6A2 P23975 3/20 0.36
SLC6A3 Q01959 2/20 0.36
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11013326 0.84 KDM4E (0.45) UHRF1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL19824289 0.82 UHRF1 (0.41) UHRF1KDM4EALDH1A1HPGDHSD17B10
Hydrochloric Acid SCHEMBL11468401 0.82 KDM4E (0.44) UHRF1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL7120097 0.79 NOS3 (0.63) UHRF1NOS3NOS1NOS2SLC6A4
SCHEMBL16517754 0.78 PDXK (0.41) UHRF1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL29425138 0.78 PDXK (0.41) UHRF1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL25652153 0.78 NOS3 (0.42) UHRF1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL20158091 0.78 KDM4E (0.41) UHRF1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL10330646 0.78 UHRF1 (0.48) UHRF1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL7046428 0.78 NOS3 (0.68) KDM4EALDH1A1HPGDHSD17B10NOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183221-A1 PYRIDINE DERIVATIVE AND APPLICATION THEREOF NICOYA THERAPEUTICS (SHANGHAI) CO., LTD (CN) 2023-06-15 US disclosed
EP-2838891-B1 AROMATIC RING COMPOUND AS GHRELIN O-ACYLTRANSFERASE INHIBITOR TAKEDA PHARMACEUTICALS CO (JP) 2017-08-02 EP disclosed
WO-2016128529-A1 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2016-08-18 WO disclosed
US-9238639-B2 Aromatic ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-19 US disclosed
US-6169092-B1 ANTIINFLAMMATORY AGENTS BAYER AKTIENGESELLSCHAFT (DE) 2001-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183221-A1 PYRIDINE DERIVATIVE AND APPLICATION THEREOF XDH, CYP11B2, DPYD UHRF1 4700/4885KDM4E 1986/4885ALDH1A1 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.